高HIV负担环境下Xpert MTB/RIF、Xpert Ultra与Abbott RealTime MTB诊断肺结核的性能比较
该研究在高HIV流行环境中招募有症状成人,每人提供4份痰标本,以培养为参考标准,比较Xpert MTB/RIF、Xpert Ultra和RealTime MTB的诊断性能。HIV感染占62%,中位CD4计数220 cells/µl。Ultra敏感性最高(89.3%),Xpert MTB/RIF特异性最高(100%);在涂阴患者中Ultra敏感性高于Xpert MTB/RIF,但差异未达统计学显著。
要点
- Ultra敏感性最高(89.3%),但特异性低于Xpert MTB/RIF(95.6% vs 100%)。
- 涂阴患者中Ultra敏感性64.7%,高于Xpert MTB/RIF的41.2%。
- HIV感染者中Ultra敏感性87.5%,高于RT-MTB的68.6%(P=0.03)。
核心结论
- Ultra在高HIV负担环境中敏感性最高,尤其在涂阴和HIV感染者中,但伴随特异性下降。
研究设计与样本
- 前瞻性研究,从三个门诊站点招募有症状成人,每人提供4份痰标本,以培养为参考标准。
- HIV感染占62%,中位CD4计数220 cells/µl。
主要发现
- Ultra敏感性89.3%(95%CI 78.1-96),Xpert MTB/RIF为82.1%(95%CI 69.6-91.1;P=0.12),RT-MTB为78.6%(95%CI 65.6-88.4;P=0.68)。
- Xpert MTB/RIF特异性100%(95%CI 98-100),RT-MTB为96.7%(95%CI 92.9-98.8;P=0.03),Ultra为95.6%(95%CI 91.5-98.1;P=0.08)。
- 涂阴患者中Ultra敏感性64.7%(95%CI 38.3-85.8),Xpert MTB/RIF为41.2%(95%CI 18.4-67.1;P=0.12)。
- 同一痰标本沉淀物比较,总体队列中Ultra敏感性88.9%(95%CI 77.4-95.8),RT-MTB为77.8%(95%CI 64.4-88;P=0.03)。
- HIV感染者中Ultra敏感性87.5%(95%CI 71-96.5),RT-MTB为68.6%(95%CI 50-83.9;P=0.03)。
临床怎么用
- 在高HIV负担和涂阴疑似结核患者中,可优先考虑Ultra以提高敏感性,但需注意其特异性略低。
局限性
- Ultra与Xpert MTB/RIF及RT-MTB的敏感性差异未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
More sensitive tests are needed for the diagnosis of smear-negative and HIV-associated tuberculosis. This study compares the sensitivities and specificities of three molecular tests, namely, the Xpert MTB/RIF test, the Xpert Ultra (Ultra), and RealTime MTB (RT-MTB), in a high HIV prevalence setting. Symptomatic adults were recruited from three outpatient sites, and each provided 4 sputum specimens. The diagnostic performance of Xpert MTB/RIF, Ultra, and RT-MTB was evaluated, with culture as a reference standard. HIV infection occurred in 62% of patients, with a median CD4 count of 220 cells/µl. The Ultra test had the highest sensitivity of 89.3% (95% confidence interval [CI], 78.1 to 96) compared to those of the Xpert MTB/RIF at 82.1% (95% CI, 69.6 to 91.1; P = 0.12) and RT-MTB at 78.6% (95% CI, 65.6 to 88.4; P = 0.68). The specificity was highest with the Xpert MTB/RIF at 100% (95% CI, 98 to 100), followed by RealTime MTB at 96.7% (95% CI, 92.9 to 98.8; P = 0.03) and the Ultra at 95.6% (95% CI, 91.5 to 98.1; P = 0.08). In patients with smear-negative disease, the Ultra was more sensitive than the Xpert MTB/RIF (64.7% [95% CI, 38.3 to 85.8] versus 41.2% [95% CI, 18.4 to 67.1], respectively; P = 0.12), and RT-MTB performed equally to Xpert MTB/RIF. In a comparison of the Ultra and RT-MTB on the same sputum specimen pellets, the Ultra was more sensitive than RT-MTB in the overall cohort (88.9% [95% CI, 77.4 to 95.8] versus 77.8% [95% CI, 64.4 to 88], respectively; P = 0.03) and among people with HIV (87.5% [95% CI, 71 to 96.5] versus 68.6% [95% CI, 50 to 83.9], respectively; P = 0.03). Although these results did not reach statistical significance, they suggest that the Ultra is more sensitive than the Xpert MTB/RIF and RT-MTB, most prominently in smear-negative disease. This was accompanied by a loss of specificity.
引用
- Berhanu RH, David A, da Silva P, et al. Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018. PMID: 30305387. doi:10.1128/JCM.00560-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。